“The biggest edge Metropolis has is nearly 4,000 varieties of tests and profiles, that is everything potentially possible globally. Our ratio of specialised test is almost 40 per cent of revenue,” Shah said on ETNow.
As of December 31, Metropolis’ network consists of 115 clinical laboratories, comprising a global reference point in Mumbai, 14 regional reference units, 56 satellite labs and 44 express facilities. They offered a broad range of around 3,487 clinical laboratory tests and 530 profiles.
Its Rs 1,204-crore initial public offer (IPO) opened for subscription on Wednesday. It allotted Rs 530.05 crore worth of shares to 26 anchor investors at Rs 880 apiece, a day before the opening of the offering.
“We developed a very marquee list of anchor investors which we were very happy with. We have names like Capital International, Neuberger, First State, Grandeur Peak and JPMorgan, all of whom are investors as FIIs ,” said Shah.
“We also have Birla MF, Sundaram and UTI, very good names when it comes to domestic institutional investors. We have a good list of people and very well diversified portfolio,” she said.
The company, according to Shah, does not require primary capital because it has a pretty high Ebitda to cash conversion ratio. “Therefore, the company continues to have capital and internal accruals to grow on its own and also do small acquisitions,” she added.
